Company Overview and News

 
PRESS DIGEST- Financial Times - April 16

2018-04-16 reuters
April 16 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
Upvote Downvote

 
What Lies Ahead for France ETFs?

2018-04-13 zacks
The French economy grew slower than estimated, per the Bank of France, primarily owing to a slowdown in manufacturing activity. The bank’s lower growth estimate for the first quarter is indicative of a somewhat broader slowdown in the Euro zone. European Central Bank (ECB) Executive Board member Benoit Coeure thinks the Euro bloc is witnessing a correction rather than a slowdown, per a Reuters article.
Upvote Downvote

 
European Buyers Go Shopping for U.S. Companies - WSJ

2018-04-07 wsj
European executives are targeting U.S. companies as a brighter economic landscape at home and abroad boosts buyer confidence.
Upvote Downvote

 
UPDATE 1-Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

2018-03-10 reuters
March 10 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.
Upvote Downvote

 
Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

2018-03-10 reuters
March 10 (Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.
Upvote Downvote

3
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

2018-02-28 investorplace
After rising 16.3% last year, the Large Cap Pharmaceutical industry has risen 1.9% this year so far. It has however underperformed the 4% gain for the S&P 500 in the same time frame.
Upvote Downvote

 
Scientists Want to Completely Rethink How They Make the Flu Vaccine - Bloomberg

2018-02-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

5
BioXcel Therapeutics Seeks $69 Million U.S. IPO

2018-02-16 seekingalpha
The firm is using the advanced data and AI technologies of its parent company to improve its drug development efforts.
Upvote Downvote

2
Berkshire buys Teva, feels IBM blues as Apple becomes top investment

2018-02-15 reuters
(Reuters) - Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) on Wednesday disclosed a new stake in generic drugmaker Teva Pharmaceutical Industries Ltd (TEVA.TA) and said it bought more shares of Apple Inc (AAPL.O), which surpassed Wells Fargo & Co (WFC.N) as its largest common stock investment.
Upvote Downvote

 
Berkshire buys Teva, feels IBM blues as Apple becomes top investment

2018-02-15 themalaymailonline
In a regulatory filing detailing its US-listed stock holdings as of December 31, Berkshire reported owning about 18.9 million Teva American depositary receipts, worth about US$358 million. — Reuters pic
Upvote Downvote

 
Berkshire buys Teva, feels IBM blues as Apple becomes top investment

2018-02-15 in.reuters
(Reuters) - Warren Buffett’s Berkshire Hathaway Inc on Wednesday disclosed a new stake in generic drugmaker Teva Pharmaceutical Industries Ltd and said it bought more shares of Apple Inc, which surpassed Wells Fargo & Co as its largest common stock investment.
Upvote Downvote

 
Regeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript

2018-02-08 seekingalpha
Welcome to the Regeneron Pharmaceuticals Q4 2017 Earnings Conference Call. My name is Jason, and I will be your operator. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Also, please note this conference is being recorded.
Upvote Downvote

 
UPDATE 2-Regeneron profit beats estimates on strong sales of key drugs

2018-02-08 reuters
(Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc’s (REGN.O) quarterly profit and revenue beat estimates, helped by strong demand for its new eczema drug Dupixent and its flagship eye treatment Eylea.
Upvote Downvote

 
10 Stocks to Ride Out the Market Storm | InvestorPlace

2018-02-06 investorplace
To put it bluntly, the past few days have been miserable for most investors. The S&P 500 is down more than 7% since its all-time high two Fridays ago. And the echoes of “melt up” chatter are still ringing in investors’ ears.
Upvote Downvote

 
An Earnings Miss Ushers in an Era of Stagnation for Amgen, Inc. Stock

2018-02-02 investorplace
After multiple quarters of beating expectations, Amgen, Inc. (NASDAQ:AMGN) shocked the market by missing both quarterly and annual estimates. Both revenues and earnings came in well below expectations, indicating the company is stuck in neutral.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...